
Crekuff-AT Syrup by Coniak Lifesciences is a prescription respiratory formulation containing Ambroxol Hydrochloride, Guaiphenesin, Terbutaline Sulphate and Menthol. This combination is intended for the management of selected respiratory conditions involving productive cough, chest congestion, thick mucus and bronchospasm.
Ambroxol Hydrochloride is a mucolytic medicine that helps reduce the thickness of respiratory mucus, making it easier to clear from the airways. Guaiphenesin is an expectorant that helps loosen respiratory secretions and supports mucus removal through coughing.
Terbutaline Sulphate is a beta-2 adrenergic bronchodilator that relaxes airway smooth muscles and may help relieve reversible airway narrowing and associated wheezing.
Menthol provides a cooling sensation that may temporarily soothe mild throat irritation and discomfort.
Crekuff-AT Syrup may be prescribed for selected respiratory conditions where mucus clearance and bronchodilation are both considered medically appropriate. It is not routinely indicated for uncomplicated viral coughs or common colds.
Available in a 100 ml bottle, Crekuff-AT Syrup should be taken strictly according to a registered medical practitioner's prescription. The dosage and treatment duration depend on the patient's age, respiratory condition and medical history.
Prices are indicative and set by the listing company. Confirm net rates, packing and stock availability directly with the supplier.
Coniak Lifesciences is a WHO-GMP and ISO 9001:2015 certified pharmaceutical and PCD (Propaganda Cum Distribution) pharma franchise company based in Panchkula, Haryana, India.
Key Company Details
• Established: 2014
• Headquarters: Plot No. 208, Industrial Area, Phase-1, Panchkula, Haryana, 134113
• Certifications: WHO-GMP and ISO certified
• Phone Number: +91-9570599567
• Official Website: Coniak Lifesciences
Core Operations & Offerings
• Product Formulations: Manufactures and supplies allopathic, herbal, Ayurvedic, and nutraceutical medicines.
• Dosage Forms: Tablets, capsules, softgels, syrups, dry syrups, injections, ointments, protein powders, pediatric drops, and dental solutions.
• Featured Brands: Conipraz LSR, Itrarap 100, Conisure P, Cincred 25, and Coniphage-N.
• Business Model: Offers pan-India PCD pharma franchise opportunities with monopoly rights alongside third-party and contract manufacturing services.
• Investment Range: Franchise partnerships typically require an initial investment ranging from ₹50,000 to ₹1.5 lakh depending on the product range.
Would you like details on their product catalog, monopoly territory availability, or franchise terms?